Exosomes in Post Therapy Surveillance
Exosomes and their associated cargo hold promise in their application as
a non-invasive biomarker for DLBCL patients. They could be of great
benefit in post treatment surveillance of DLBCL patients as a means to
avoid radiation exposure of PET scans and unnecessary testing associated
with false-positive PET scans. Di et al identified a panel of five
circulating exosomal miRNAs as noninvasive biomarkers of DLBCL
consisting of hsa-miR-379-5p, hsa-miR-135a-3p, hsa-miR-4476,
hsa-miR-483-3p and hsa-miR-451a (99). hsa-miR-379-5p, hsa-miR-135a-3p,
hsa-miR-4476 were overexpressed in DLBCL compared to healthy controls,
while hsa-miR-483-3p and hsa-miR-451a were expressed at lower levels.
The panel had an AUC of 0.951 (95% CI0.847-0.993) in the testing phase,
0.841 (95% CI, 0.767-0.900) in the validation phase and 0.824 (95% CI,
0.760-0.877) in the combined testing and validation phase.